GB2489180A - Method of predicting capecitabine toxicity - Google Patents

Method of predicting capecitabine toxicity Download PDF

Info

Publication number
GB2489180A
GB2489180A GB1212893.0A GB201212893A GB2489180A GB 2489180 A GB2489180 A GB 2489180A GB 201212893 A GB201212893 A GB 201212893A GB 2489180 A GB2489180 A GB 2489180A
Authority
GB
United Kingdom
Prior art keywords
predicting
capecitabine
cda
mthfr
toxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB1212893.0A
Other versions
GB2489180B (en
GB201212893D0 (en
Inventor
Aathavan Lo-Ganayagam
Jeremy David Sanderson
Anthony Marin Marinaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guys and St Thomas NHS Foundation Trust
Original Assignee
Guys and St Thomas NHS Foundation Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guys and St Thomas NHS Foundation Trust filed Critical Guys and St Thomas NHS Foundation Trust
Publication of GB201212893D0 publication Critical patent/GB201212893D0/en
Publication of GB2489180A publication Critical patent/GB2489180A/en
Application granted granted Critical
Publication of GB2489180B publication Critical patent/GB2489180B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

A method of predicting capecitabine toxicity in a patient includes determining a patient's genotype for one or more genetic variants in one or more genes involved in capecitabine metabolism. The genetic variant may be a single nucleotide polymorphism in the gene encoding MTHFR and/or the gene encoding CDA. The genetic variant may be found at MTHFR 677, and/or at MTHFR 1298, and/or CDA - 92 and/or at CDA -451.
GB1212893.0A 2009-12-21 2010-12-21 Predicting capecitabine toxicity Expired - Fee Related GB2489180B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0922356A GB0922356D0 (en) 2009-12-21 2009-12-21 Predicting capecitabine toxicity
PCT/GB2010/002304 WO2011077080A1 (en) 2009-12-21 2010-12-21 Method of predicting capecitabine toxicity

Publications (3)

Publication Number Publication Date
GB201212893D0 GB201212893D0 (en) 2012-09-05
GB2489180A true GB2489180A (en) 2012-09-19
GB2489180B GB2489180B (en) 2014-03-12

Family

ID=41717349

Family Applications (2)

Application Number Title Priority Date Filing Date
GB0922356A Ceased GB0922356D0 (en) 2009-12-21 2009-12-21 Predicting capecitabine toxicity
GB1212893.0A Expired - Fee Related GB2489180B (en) 2009-12-21 2010-12-21 Predicting capecitabine toxicity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB0922356A Ceased GB0922356D0 (en) 2009-12-21 2009-12-21 Predicting capecitabine toxicity

Country Status (2)

Country Link
GB (2) GB0922356D0 (en)
WO (1) WO2011077080A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014137705A1 (en) * 2013-03-05 2014-09-12 The Board Of Trustees Of The Leland Stanford Junior University Assessing risk for encephalopathy induced by 5-fluorouracil or capecitabine
CN104975014A (en) * 2015-07-08 2015-10-14 南昌艾迪康临床检验所有限公司 Primers and method for detecting 79th site, 208th site and 435th site of CDA gene

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007150069A2 (en) * 2006-06-23 2007-12-27 Myriad Genetics, Inc. Dpyd gene variants and use thereof
WO2009021551A1 (en) * 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007150069A2 (en) * 2006-06-23 2007-12-27 Myriad Genetics, Inc. Dpyd gene variants and use thereof
WO2009021551A1 (en) * 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG, BERLIN, Vol. 63, 2009, MERCIER C ET AL: "Early severe toxicities after capecitabine intake...", Pages 1177-1180 *
CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, Vol. 14, 2008, SHARMA ROHINI ET AL: "Thymidylate synthase and methylene....", Pages 817-825. *
CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, Vol. 27, 2005, WALKO C M ET AL: "Capecitabine: A review", Pages 23-44 *
CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, ELSEVIER SCIENCE IRELAND, Vol. 68, 2008, BONONI A ET AL : "Methylenetetrahydrofolate reductase (MTHFR) gene......", Pages s42-s43 *
CURRENT DRUG METABOLISM MAY 2008 LNKD-PUBMED, Vol. 9, 2008, RIBELLES N ET AL: "A carboxylesterase 2 gene polymorphism....", Pages 336-343. *
JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, Vol. 25, 2007, SUGIYAMA EMIKO ET AL: "Pharmacokinetics of gemcitabine in Japanes cancer patients....", Pages 32-42. *
PHARMACOGENOMICS JOURNAL, NATURE PUBLISHING GROUP, GB, Vol. 5, 2005, MARING J G ET AL: "Genetic factors influencing pyrimidine....", Pages 226-243. *
TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 28, 2007, MERCIER ET AL: "Severe or lethal toxicities upon capecitabine intake...", Pages 597-598 *

Also Published As

Publication number Publication date
GB0922356D0 (en) 2010-02-03
GB2489180B (en) 2014-03-12
WO2011077080A1 (en) 2011-06-30
GB201212893D0 (en) 2012-09-05

Similar Documents

Publication Publication Date Title
WO2009059317A3 (en) Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
GB2477868A (en) Methods and systems for incorporating multiple environmental and genetic risk factors
IL211140A (en) Method of determining risk of alzheimer's disease based on the presence or absence of variants in the tomm40 gene
EP2064345A4 (en) Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
EP2310525A4 (en) Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
EP2253713A4 (en) Method for measuring chromosome, gene or specific nucleotide sequence copy numbers using snp array
IL200453A0 (en) Genetic susceptibility variants associated with cardiovascular disease
WO2011097644A3 (en) Selective reduction of allelic variants
WO2012018613A3 (en) Genetic make-up modifies cancer outcome
WO2011006070A3 (en) Genetic association of polymorphisms in perilipin (plin) gene with resistance to weight loss
EP2082062A4 (en) Methods of allele typing
MX2016005003A (en) Genetic markers predictive of response to glatiramer acetate.
PL1730315T3 (en) Polymorphisms in nod2/card15 gene
EP1999278A4 (en) Genetic markers for predicting disease and treatment outcome
PL2816118T3 (en) Methods for delivering genes
EP2210942A4 (en) Gene associated with liver cancer, and method for determination of the risk of acquiring liver cancer
EP2017355A4 (en) Gene associated with arteriosclerotic disease, and use thereof
GB0613844D0 (en) Methods and products for in vitro genotyping
EP2134863A4 (en) Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
IL198354A0 (en) Genetic variations associated with tumors
WO2007095580A3 (en) Treatment response in generalized social phobia
GB2489180A (en) Method of predicting capecitabine toxicity
EP2099909A4 (en) Method of determining the haplotype of multiple allelic genes
IL172657A0 (en) Adaptive computer-based evaluation with constrained genetic algorithm
WO2010014905A3 (en) Polymorphisms in the xbp-1 gene associated with inflammatory bowel disease

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20161221